Meloxicam is an oxicam-class medication that belongs to the nonsteroidal anti-inflammatory drugs (NSAIDs) used for pain management. Like other NSAIDs, it is primarily metabolized by CYP2C9.
Meloxicam (Dosage)
Meloxicam is an NSAID analgesic used to treat osteoarthritis and rheumatoid arthritis in adults. Meloxicam is approved for use in some countries, such as the United States, for the management of pain and inflammation associated with juvenile idiopathic arthritis.
MECHANISM OF ACTION
Meloxicam is a potent inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), which works by reducing the synthesis of prostaglandins, substances that mediate pain, inflammation, and fever. It acts preferentially on COX-2, which reduces the risk and severity of gastrointestinal adverse effects typical of NSAIDs, although not completely.
CONTRAINDICATIONS
Treatment with meloxicam is contraindicated in the following cases:
- Patients with hypersensitivity to NSAIDs, including acetylsalicylic acid.
- In some countries, such as Spain, it is contraindicated in children and adolescents.
- History of gastrointestinal perforation or bleeding related to NSAID use.
- Presence of active or previous gastrointestinal ulcers or bleeding.
- Cerebrovascular hemorrhages or other types of active bleeding.
- During the third trimester of pregnancy.
- Patients with severe kidney, liver, and heart problems.
SIDE EFFECTS
The most frequent adverse reactions are indigestion, nausea, abdominal pain, vomiting, constipation, diarrhea, gas, and headache.
INTERACTIONS
Meloxicam can interact with multiple medications, so it is recommended to inform your doctor of all the medications you are taking. Meloxicam interacts with NSAIDs (such as acetylsalicylic acid and ibuprofen) and anticoagulant agents (such as warfarin) and antiplatelet agents (e.g., clopidogrel) and can lead to an increased risk of bleeding. It also interacts with corticosteroids, immunosuppressants (cyclosporine and tacrolimus), lithium, selective serotonin reuptake inhibitors (SSRIs), diuretics (spironolactone), oral antidiabetics (sulfonylureas and nateglinide), methotrexate, deferasirox, some antibiotics (trimethoprim), among other medications.
BRAND NAMES
- Anjeso®
- Qmiiz®
- Mobic®
- Vivlodex®
- Zynrelef®
Genes analyzed
Bibliography
Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020 Aug;108(2):191-200.
